Developed in Collaboration with Leading Scientists, New ResMed-Supported Research at ATS 2024 Provides Evidence of the Effectiveness and Critical Role of Positive Airway Pressure Therapy

Core Insights - ResMed supported 26 abstracts presented at the American Thoracic Society International Conference, highlighting the effectiveness of PAP therapy in treating sleep-disordered breathing and its cardiovascular health benefits [1][10] Group 1: PAP Therapy and Sleep Disorders - Studies demonstrated that PAP therapy continues to lower risks associated with sleep disorders, with a meta-study showing a 37% lower mortality rate in patients with PAP-treated obstructive sleep apnea (OSA) compared to untreated OSA [3] - An analysis of 17,000 treatment-naïve patients indicated that PAP treatment reduces hospitalization rates over the first four years of treatment, correlating PAP therapy use with reduced healthcare resource utilization [4] Group 2: Prevalence and Future Trends of OSA - Research projected a 27.6% increase in OSA cases in the U.S. by 2050 among individuals aged 30-70, with an overall prevalence of 26% expected in this demographic due to aging and rising BMI trends [5] - The increasing prevalence of OSA is anticipated to drive higher reliance on PAP therapy, which remains the gold standard for treatment [5] Group 3: GLP-1 Receptor Agonists and PAP Therapy - A study found that the use of GLP-1 receptor agonists did not lead to higher discontinuation rates of PAP therapy; instead, patients adhering to GLP-1 medication had higher levels of PAP therapy use compared to non-adherent patients [2][8] Group 4: Adaptive Servo-Ventilation (ASV) Therapy - Studies on ASV therapy showed reduced symptom burden and improved quality of life for patients with treatment-emergent or persistent central sleep apnea (TE-CSA) [6] - Another study indicated that ASV treatment for patients on long-term opioid therapy resulted in a median reduction in Epworth Sleepiness Scale values, demonstrating lower symptom burden and improved quality of life [7] Group 5: Non-Invasive Ventilation (NIV) in COPD - Research involving nearly 50,000 adults with COPD indicated that long-term home use of NIV is strongly associated with a reduced risk of death [9]